Edition:
United States

Flamel Technologies SA (FLML.OQ)

FLML.OQ on NASDAQ Stock Exchange Global Market

13.53USD
26 Sep 2016
Change (% chg)

$-0.21 (-1.53%)
Prev Close
$13.74
Open
$13.53
Day's High
$13.53
Day's Low
$13.53
Volume
865
Avg. Vol
52,136
52-wk High
$19.76
52-wk Low
$7.56

Latest Key Developments (Source: Significant Developments)

Flamel technologies announces shareholder approval of cross-border merger
Friday, 12 Aug 2016 07:30am EDT 

Flamel Technologies Sa : Avadel Pharmaceuticals limited will re-register as irish public limited co and will be known as Avadel Pharmaceuticals Plc . Flamel technologies announces shareholder approval of cross-border merger . Received shareholder approval to reincorporate its country of domicile to Ireland from France via a cross-border merger .Under terms of reincorporation, Flamel will merge with and into its wholly owned subsidiary, Avadel Pharmaceuticals Ltd.  Full Article

Flamel Technologies reports Q2 GAAP loss per share $0.48
Monday, 8 Aug 2016 06:05am EDT 

Flamel Technologies SA : Total revenue for Q2 2016 was $38.9 million, compared to $48.6 million during same period last year . Q2 adjusted loss per share $0.02 . Q2 GAAP loss per share $0.48 . Has lowered its 2016 research and development spending guidance to range or $30 to $40 million .2016 revenue guidance increased to $125 to $140 million.  Full Article

Janus Capital Management reports 5.3 pct passive stake in Flamel Technologies - SEC filing
Friday, 8 Jul 2016 12:44pm EDT 

Janus Capital Management LLC:Janus Capital Management reports 5.3 percent passive stake in Flamel Technologies as of June 30 versus earlier passive stake of 10.7 percent as of Dec. 31, 2015.  Full Article

Flamel Technologies maintains full year 2016 revenue guidance
Monday, 9 May 2016 07:30am EDT 

Flamel Technologies SA : Maintaining its full year 2016 revenue guidance . Expects research & development expenses to be in range of $35 - $50 million, up from $25.6 million in 2015 . FY 2016 revenue view $124.6 million -- Thomson Reuters I/B/E/S . Flamel Technologies reports first quarter 2016 results . Q1 adjusted earnings per share $0.04 . Q1 GAAP loss per share $0.15 . Q1 revenue $36.2 million versus I/B/E/S view $34.1 million . Sees FY 2016 revenue $110 million to $130 million .Q1 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.  Full Article

Flamel Technologies SA receives FDA approval of Akovaz
Monday, 2 May 2016 07:30am EDT 

Flamel Technologies SA:Says FDA has approved company's new drug application for Akovaz.Flamel expects to launch Akovaz during third quarter 2016 in a strength of 50 mg/mL.  Full Article

Flamel Technologies SA announces positive interim results of a first-in-Man Clinical Trial With Medusa Exenatide
Tuesday, 22 Dec 2015 08:00am EST 

Flamel Technologies SA:Announces positive interim results of a first-in-man clinical trial with Medusa(TM) exenatide.Study achieved all safety and pharmacokinetic assessment objectives throughout ascending single dose administrations of ft228.Says Flamel plans to initiate a phase 1b study of ft228 in type 2 diabetes mellitus patients in Q1 2016.  Full Article

Flamel Technologies SA Appoints Michael Kanan Chief Financial Officer
Monday, 23 Nov 2015 08:00am EST 

Flamel Technologies SA:Appointed Michael F. Kanan as its Senior Vice President and Chief Financial Officer.  Full Article

Flamel Technologies announces FDA acceptance of third NDA filing
Wednesday, 9 Sep 2015 08:00am EDT 

Flamel Technologies SA:Announces FDA acceptance of third NDA filing.Says received PDUFA date of April 30, 2016 from the U.S. food and drug administration.Says estimates current U.S. market sales of unapproved versions of this drug are in range of $70-$80 million per year.  Full Article

Flamel Technologies SA reaffirms FY 2015 product revenue guidance
Thursday, 30 Jul 2015 07:30am EDT 

Flamel Technologies SA:Reaffirms product revenue guidance for FY 2015 of $170-185 million for both Bloxiverz and Vazculep.  Full Article

Flamel Technologies SA Announces Positive Results From First Clinical Trials With Trigger Lock Hydromorphone Abuse-Deterrent Product
Monday, 29 Jun 2015 07:30am EDT 

Flamel Technologies SA:Says positive results from first clinical trials with trigger Lock hydromorphone abuse-deterrent product.In both studies FT227 was well tolerated and no serious adverse events were reported.  Full Article

BRIEF-Flamel technologies announces shareholder approval of cross-border merger

* Avadel Pharmaceuticals limited will re-register as irish public limited co and will be known as Avadel Pharmaceuticals Plc